EpiPen’s Price Hikes: Greed or Gov’t Cronyism?
THE ISSUE: Widespread outrage over EpiPen’s price increase from $57 in 2007 to around $600 today.
I read with interest Ira Stoll’s column “Killer Cronyism” (PostOpinion, Aug. 29).
However, Stoll’s column omits an important fact: Namely that Mylan has no competition for production of the EpiPen, and the party responsible for this phenomenon is the Food and Drug Administration.
The efforts by Congress to address the issues Stoll raises should be focused on oversight of the FDA, with those members with conflicts of interest recusing themselves.
The status quo on green-lighting of pharmaceuticals stinks. Should it continue, critical pharmaceuticals will not only be expensive, but also hard to obtain, as drug companies will move with greater speed offshore to join medical-device makers. Lee David Klein Poughkeepsie I’m incredulous at the price increase of EpiPens. I guess saving a life has a hefty price tag. Maybe some of the $19 million compensation for the CEO of Mylan can be used to lower the price of EpiPens.
Or perhaps some of the billions we give to other countries could be better used to help our own children.
Are we world leaders or world fools? I don’t know if either the clown or the joker running for president could solve this. Craig Gunther Toms River, NJ
I guarantee that when Hillary Clinton spoke out against the massive price hike of EpiPens by Mylan, it was before she knew that the company’s CEO is the daughter of Democratic Sen. Joe Manchin.
People need to understand that greed doesn’t only apply to Republicans. Robert Sieger Manhattan
I don’t understand why the EpiPen is so expensive.
The patent on epinephrine, the active ingredient in the EpiPen, has long since expired.
Why doesn’t a drug company step in and create a generic substitute?
Several different companies are trying to make a substitute but are caught within the corrupt regulatory system. Charlie Honadel Staten Island